Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | PHASE1 | ACTIVE NOT_RECRUITING | 98 | — | — | May 31, 2023 | Jun 1, 2027 | Aug 15, 2025 | 10 | United States |
Incidence, nature and severity of treatment-related adverse events
Incidence and nature of dose-limiting toxicities
Measured by RECIST 1.1 and iRECIST
| Arm | Type | Description |
|---|---|---|
| Part A - SNS-101 Monotherapy Dose Escalation and Dose Expansion | EXPERIMENTAL | SNS-101 IV alone every 21 days. Patients will initially enroll in dose escalation cohorts. |
| Part B - SNS-101 in combination with cemiplimab and Dose Expansion | EXPERIMENTAL | SNS-101 IV and cemiplimab IV every 21 days. Patients will initially enroll in dose escalation cohorts. |
| Part C - Cohort Expansion - SNS-101 alone or in combination with cemiplimab | EXPERIMENTAL | SNS-101 IV alone or in combination with cemplimab IV every 21 days at the RP2D. |
| Name | Type | Description |
|---|---|---|
| SNS-101 (anti-VISTA) | DRUG | SNS-101 IV every 21 days. |
| Cemiplimab | DRUG | Cemiplimab IV every 21 days. |
Key Inclusion Criteria: * Histologically or cytologically documented locally advanced, unresectable or metastatic solid tumor. * Having received and failed or was intolerant to standard of care for advanced disease or not eligible for standard of care therapy with the following tumor types for pati...